EC approves Menarini and NewAmsterdam’s obicetrapib therapies
RegulatoryapprovedUbesloEvlarcoPositive
AI Analysis
Summary
The European Commission has granted marketing authorisation to NewAmsterdam Pharma and Menarini Group for obicetrapib therapies Ubeslo and Evlarco. This represents a significant regulatory milestone for the companies' cholesterol-lowering treatment candidates.
Outcome Details
EC marketing authorisation granted
Importance:8/10
Sentiment:
0.85
EC approvalmarketing authorisationregulatory successobicetrapib
Related Companies
Read the original article
Published by Pharmaceutical Technology on September 22, 2026 8:50 AM